Earnings 2026-07-2352W high -68.8%52W low +42.6%Market cap $63MAvg volume 16K
Company Overview
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q1 | -0.95 | $0 | -$15M |
| 2025 Q4 | -0.62 | $0 | -$7M |
| 2025 Q3 | -3.01 | $0 | -$27M |
| 2025 Q2 | -0.06 | $0 | -$3M |
| 2025 Q1 | -0.18 | $0 | -$11M |
| 2024 Q4 | -0.19 | $0 | -$6M |
| 2024 Q3 |
